US Contrast Ultrasound Market: FDA Approvals & Reimbursement Challenges

 

This analysis is brought to you by Inkwood Research, a leading market intelligence firm specialising in North American diagnostic imaging markets, FDA regulatory pathways, and clinical adoption dynamics for advanced ultrasound technologies. Our research team draws on deep expertise in contrast agent ecosystems, US hospital reimbursement structures, cardiology and radiology workflow integration, and the regulatory evolution of ultrasound contrast agents across American healthcare institutions. Through strategic partnerships with US hospital networks, radiology society stakeholders, and healthcare policy consultants, we deliver actionable intelligence for businesses navigating the United States contrast ultrasound market.

Table of Contents

• What Is the Status of Contrast Ultrasound in the United States?
• How Does the FDA Approval Pathway Shape US CEUS Adoption?
• What Reimbursement Challenges Has the US Market Faced?
• How Are Ambulatory Surgical Centers Driving CEUS Growth?
• What Emerging Indications Are Expanding the US Contrast Ultrasound Market?
• WhoAre the Top 4 Players in the United States Contrast Ultrasound Market?
• Key Takeaways
• Conclusion
• Frequently Asked Questions

TL;DR

The United States contrast ultrasound market is the world's largest by value, projected to grow from US$729.85 million in 2026 to US$1,088.15 million by 2034 at a 5.12% CAGR. Yet the US remains paradoxically behind Europe and Asia in contrast ultrasound adoption breadth. A complex interplay of FDA approval history, inconsistent reimbursement structures, and operator training gaps has shaped a market that is simultaneously vast and underutilised. Understanding the regulatory architecture and where it is headed is essential for every stakeholder in this space.

This blog is directly relevant for radiologists, cardiologists, and hospital procurement leaders operating across US healthcare systems. Additionally, pharmaceutical executives developing contrast enhanced ultrasound agent portfolios, health technology investors tracking the enhanced ultrasound industry, reimbursement strategy consultants, and ambulatory surgical centers evaluating advanced imaging technologies will find rigorous, evidence-grounded insights in this analysis.

What Is the Status of Contrast Ultrasound in the United States?

Ask any experienced European or Asian radiologist about contrast ultrasound in the US, and the response is often one of mild bewilderment. While Europe integrated contrast enhanced ultrasonography into hepatic, renal, and vascular practice decades ago, the US remained, until relatively recently, a market where CEUS was primarily a cardiology tool. The reasons are structural, rooted in a regulatory environment that required explicit FDA approval for each specific indication, rather than permitting the broad, clinical-practice-led adoption that characterised European markets.

A Market Rich in Potential, Historically Constrained

Today, the UnitedStates contrast ultrasound market occupies a transitional moment. FDA approvals for hepatic and paediatric applications have changed the landscape considerably. The American Institute of Ultrasound in Medicine (AIUM) 2024 updated practice parameters for CEUS covering liver, renal, and vascular applications now provide the institutional framework that hospitals need to build structured CEUS programmes, not just isolated pockets of academic use. Furthermore, growing clinical evidence and increasing operator familiarity are gradually normalising contrast ultrasound beyond echocardiography.

How Does the FDA Approval Pathway Shape US CEUS Adoption?

Understanding what is a contrast enhanced ultrasound in the US regulatory context requires appreciating the FDA's indication-specific approval model. Unlike drugs that receive broad approval for a therapeutic class, ultrasound contrast agents in the US require explicit approval for each clinical application, such as echocardiography, liver imaging, paediatric use, and so on. This framework has simultaneously protected patient safety and slowed adoption compared to markets where clinical practice guidelines drove utilisation.

The Three FDA-Approved Agents

Currently, three ultrasound contrast agents are FDA-approved in the United States: Lumason (Bracco Diagnostics), Definity (Lantheus Medical Imaging), and Optison (GE Healthcare). Lumason, known internationally as SonoVue, holds the broadest US indication set, covering adult echocardiography, focal liver lesion characterisation in adults and children, intravesical assessment for vesicoureteral reflux, and paediatric echocardiography.

Definity and Optison are approved for adult echocardiography. Additionally, all three agents carry a boxed warning regarding cardiopulmonary reactions, a historical legacy from the 2007 FDA caution period, though subsequent evidence strongly demonstrated their favourable safety profiles.

What Indications Remain Off-Label?

Despite Lumason's FDA approval for liver imaging, many noncardiac CEUS applications in the US, renal lesion characterisation, vascular imaging, ablation guidance, and transcranial applications, remain technically off-label.

How does contrast enhanced ultrasound works in these settings is well understood clinically; the challenge is the absence of CPT billing codes specific to noncardiac CEUS indications. This gap continues to limit adoption beyond academic medical centres, where off-label use is more readily supported by institutional infrastructure and clinical expertise.

What Reimbursement Challenges Has the US Market Faced?

Reimbursement has been, and remains, the central structural challenge for the United States contrast ultrasound market. The complexity of US payer structures means that coverage for contrast ultrasound procedures varies substantially across Medicare, Medicaid, and private insurers. For echocardiography with contrast, reimbursement pathways are well-established and predictable. For hepatic and other noncardiac CEUS applications, the pathway is more complex.

CMS Pass-Through Status and Its Impact

A pivotal milestone came when the Centers for Medicare and Medicaid Services (CMS) granted Lumason "pass-through" status for reimbursement under the Hospital Outpatient Prospective Payment System (OPPS). This status allows separate reimbursement for the contrast agent itself in outpatient hospital settings, a meaningful economic signal that accelerated CEUS investment among US hospital radiology departments. Moreover, this reimbursement development encouraged larger health systems to build structured contrast ultrasound programmes, rather than treating CEUS as an occasional, individually justified procedure.

The CPT Code Gap for Noncardiac Applications

Nevertheless, the absence of dedicated CPT codes for noncardiac CEUS applications, covering hepatic, renal, and vascular ultrasound procedures, remains a significant barrier. Radiologists performing these procedures must navigate complex billing pathways, often falling back on general ultrasound codes that do not fully capture the clinical and economic value of enhanced ultrasound. As a result, adoption outside academic medical centres has been slower than the clinical evidence base would warrant. Industry advocacy for dedicated CEUS CPT codes represents one of the most consequential ongoing regulatory efforts in the United States contrast ultrasound market.

How Are Ambulatory Surgical Centers Driving CEUS Growth?

Despite the reimbursement complexities at the systemic level, ambulatory surgical centers are emerging as active and effective adopters of contrast ultrasound in the US. The operational model of ASCs, high throughput, patient convenience, and cost efficiency, aligns naturally with CEUS's core strengths.

Why ASCs Suit CEUS Operations

·       Unlike MRI or CT suites, CEUS requires no radiation shielding, no complex installation requirements, and no lengthy patient preparation. A contrast-enhanced ultrasound examination, covering liver lesion characterisation or cardiac assessment, can typically be completed and interpreted within 30 minutes.

·       Furthermore, portable ultrasound devices with contrast-specific imaging modes from GE Healthcare, Siemens, Philips, and Mindray are now compatible with outpatient settings, meaning ASCs do not require large, expensive dedicated imaging infrastructure.

·       Additionally, software application diagnostic therapeutic platforms are transforming how ASCs manage CEUS workflows. Time-intensity curve analysis, AI-assisted perfusion quantification, and electronic reporting integrations are standardising diagnosis across operators, reducing the expertise barrier that has historically confined CEUS to fellowship-trained sonographers.

·       Consequently, ASC investment in enhanced ultrasound infrastructure is increasingly seen as a competitive differentiator and not merely a clinical upgrade.

What Emerging Indications Are Expanding the US Contrast Ultrasound Market?

· Renal and Oncological Applications

Renal lesion characterisation represents perhaps the most immediately actionable emerging indication for contrast ultrasound in the US. As AIUM 2024 practice parameters for liver, renal, and vascular CEUS provide formal clinical guidance, US nephrologists and urologists are increasingly viewing contrast enhanced ultrasonography as a safe, reliable tool for the Bosniak classification of complex renal cysts, particularly valuable for patients with chronic kidney disease who cannot safely receive nephrotoxic CT or MRI contrast agents.

· Emergency and Trauma Applications

Additionally, emergency medicine represents another high-potential frontier. Point-of-care diagnostic imaging in US emergency departments increasingly relies on bedside ultrasound, and CEUS extends its capabilities dramatically for trauma patients, where rapid solid organ perfusion assessment, typically requiring a CT, can now be performed at the bedside with a contrast-capable portable device. Moreover, for pregnant patients and paediatric trauma cases where radiation exposure carries disproportionate risk, CEUS fills a genuine clinical gap that CT cannot safely occupy.

· Therapeutic Frontiers: Sonoporation and Drug Delivery

Looking forward, molecule-targeted microbubbles and nanoparticle molecule-targeted contrast agents are opening therapeutic applications that could fundamentally reshape CEUS's role in US oncology. Sonoporation, using focused ultrasound to temporarily increase tumour cell membrane permeability, combined with targeted microbubbles, enables more efficient chemotherapeutic delivery to tumour sites. While still largely in clinical trial phases at US academic centres, these therapeutic applications represent the most transformative long-term growth vector for the United States contrast ultrasound market.

Who Are the Top 4 Players in the United States Contrast Ultrasound Market?

1. Bracco Diagnostics, Lumason

Bracco holds the most comprehensive approved indication set for contrast ultrasound in the US through Lumason. The company continues to invest in clinical evidence generation, particularly for non-hepatic applications, including renal lesion characterisation and emergency trauma imaging, with the goal of supporting future FDA indication expansions. Additionally, Bracco's physician education programmes remain central to growing CEUS utilisation beyond its established cardiology and hepatology base.

2. Lantheus Medical Imaging, Definity

Lantheus Medical Imaging is a key player in the US cardiac contrast enhanced ultrasound agent practice through Definity, used in more than 6.7 million patients worldwide. The company has been actively expanding its diagnostic imaging portfolio through acquisitions and development partnerships, positioning itself at the intersection of contrast ultrasound and advanced imaging technologies. Its strong cardiac imaging presence gives Lantheus a natural platform for CEUS-specific growth as cardiological applications continue to broaden.

3. GE Healthcare

GE Healthcare's role in the enhanced ultrasound industry spans hardware platforms, the Optison contrast agent, and, since its 2024 acquisition of Intelligent Ultrasound's clinical AI business for USD 51 million, AI-assisted scanning tools like ScanNav. These AI tools automate image acquisition guidance, reduce operator dependency, and directly support CEUS workflow scalability in US hospital outpatient and ambulatory surgical centers settings.

4. Siemens Healthineers and Philips

Siemens Healthineers received FDA clearance in August 2024 for its Acuson Origin cardiovascular ultrasound system, featuring AI capabilities capturing over 5,000 measurements per echocardiography examination with 99% diagnostic accuracy. This positions Siemens as a premium competitor for US cardiac CEUS applications, particularly at large academic medical centres. Philips, meanwhile, continues to expand its EPIQ and Affiniti contrast-capable platforms across US health systems, competing on workflow integration and image quality.

Key Takeaways

·       The United States contrast ultrasound market is projected to grow from US$729.85 million in 2026 to US$1,088.15 million by 2034 at a 5.12% CAGR, the world's largest CEUS market by value, with significant untapped clinical potential.

·       The FDA's indication-specific approval model has shaped US adoption: Lumason, Definity, and Optison are the three approved agents, with Lumason holding the broadest indication set, including hepatic and paediatric applications.

·       CMS pass-through reimbursement status for Lumason has been a meaningful catalyst for hospital adoption, but the absence of dedicated noncardiac CEUS CPT codes remains the most significant structural growth barrier.

·       Ambulatory surgical centers are emerging as efficient, high-volume CEUS adopters, benefiting from CEUS's radiation-free, rapid-turnaround characteristics and the availability of portable contrast-capable platforms.

·       Emerging indications, renal lesion characterisation, emergency trauma imaging, and therapeutic molecule-targeted microbubble applications represent the next phase of US contrast ultrasound market expansion.

·       AI integration across hardware platforms and software application diagnostic and therapeutic workflows is reducing operator dependency and enabling broader CEUS deployment beyond academic centres.

Conclusion

The United States contrast ultrasound market stands at a genuine inflection point. The regulatory foundation has solidified with FDA approvals and updated AIUM practice parameters. The economic pathway is improving with CMS pass-through status.

The clinical evidence base for enhanced ultrasound across hepatic, renal, cardiac, and emergency applications has never been stronger. What remains is the work of overcoming structural adoption barriers, CPT code expansion, operator training, and ASC integration.

Inkwood Research provides the market intelligence, competitive analysis, and regulatory insights needed to navigate this market confidently.

Connect with our team to explore how our perspective can support your positioning in the United States contrast ultrasound market.

Frequently Asked Questions

How large is the United States contrast ultrasound market?

The market is valued at US$729.85 million in 2026, projected to reach US$1,088.15 million by 2034 at a 5.12% CAGR, the largest CEUS market globally by value.

Which FDA-approved contrast agents are available in the United States?

Lumason (Bracco), Definity (Lantheus), and Optison (GE Healthcare) are the three FDA-approved US contrast ultrasound agents, each covering specific indications.

Does Medicare reimburse CEUS procedures in the US?

Lumason has CMS pass-through status for outpatient hospital reimbursement. However, noncardiac CEUS applications lack dedicated CPT codes, creating complex billing challenges.

Why is contrast ultrasound more widely used in Europe than in the US?

European markets adopted CEUS through clinical practice guidelines before the US obtained FDA approvals. The US's indication-specific regulatory model slowed non-cardiac utilisation considerably.

What are the newest CEUS indications being explored in the US?

Renal lesion characterisation, emergency trauma imaging, sonoporation-based drug delivery, and wearable ultrasound monitoring are the most actively pursued emerging US CEUS applications.

Are portable ultrasound devices capable of CEUS in US ambulatory settings?

Yes. GE Healthcare, Siemens Healthineers, Philips, and Mindray all offer portable systems with contrast-specific imaging modes suitable for US ambulatory surgical centers and emergency departments.